Table 1 Baseline characteristics
Parameter | A1 (%) | A2 (%) | B1 (%) | B2 (%) |
|---|---|---|---|---|
Sex | ||||
Male | 8 (66.7) | 10 (83.3) | 14 (87.5) | 10 (83.3) |
Female | 4 (33.3) | 2 (16.6) | 2 (12.5) | 2 (16.7) |
Age (median, range) | 57 (29–71) | 64 (43–78) | 63 (22–73) | 60.5 (48–72) |
Performance status score | ||||
0 | 2 (16.7) | 0 (0) | 1 (6.3) | 2 (16.7) |
1 | 10 (83.3) | 12 (100) | 15 (93.7) | 10 (83.3) |
Pathological type | ||||
Adenocarcinoma | 5 (41.7) | 2 (16.6) | 5 (31.3) | 2 (16.7) |
Squamous carcinoma | 5 (41.7) | 5 (41.7) | 10 (62.5) | 10 (83.3) |
Adenosquamous | 0 (0) | 2 (16.6) | 0 (0) | 0 (0) |
other | 2 (16.6) | 3 (25.0) | 1 (6.2) | 0 (0) |
PD-L1 expression | ||||
<1% | 0 (0) | 0 (0) | 0 (0) | 12 (100) |
1–49% | 0 (0) | 0 (0) | 16 (100) | 0 (0) |
≥ 50% | 12 (100) | 12 (100) | 0 (0) | 0 (0) |
Clinical stage | ||||
IIa | 0 (0) | 0 (0) | 1 (6.2) | 1 (8.3) |
IIb | 1 (8.3) | 2 (16.6) | 5 (31.3) | 3 (25.0) |
IIIa | 7 (58.3) | 9 (75.0) | 8 (50.0) | 6 (50.0) |
IIIb | 4 (33.3) | 1 (8.3) | 2 (12.5) | 2 (16.7) |
T stage | ||||
1c | 2 (16.6) | 1 (8.3) | 0 (0) | 0 (0) |
2a | 1 (8.3) | 2 (16.6) | 4 (25.0) | 2 (16.7) |
2b | 1 (8.3) | 2 (16.6) | 3 (18.8) | 3 (25.0) |
3 | 8 (66.7) | 5 (41.7) | 7 (43.8) | 5 (41.7) |
4 | 0 (0) | 2 (16.6) | 2 (12.5) | 2 (16.7) |
N stage | ||||
0 | 0 (0) | 0 (0) | 3 (18.8) | 2 (16.7) |
1 | 3 (25.0) | 8 (66.7) | 8 (50.0) | 6 (50.0) |
2 | 9 (75.0) | 4 (33.3) | 5 (31.3) | 4 (33.3) |
M stage | ||||
0 | 12 (100) | 12 (100) | 16 (100) | 12 (100) |
